c19early.org COVID-19 treatment researchCOVID-19 treatments

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD)

Keating et al., NCT04478019, SHIELD, NCT04478019, Jun 2022

Chlorhexidine for COVID-19

53rd treatment shown to reduce risk in November 2023, now with p < 0.0000000001 from 5 studies.
Lower risk for progression, cases, and viral clearance.

No treatment is 100% effective.
Protocols combine treatments.

6,700+ studies · 220+ treatments

c19early.org
Meta-analysis
245 participant chlorhexidine + PVP-I prophylaxis RCT with results not reported over 4 years after completion.
3 chlorhexidine RCTs have results missing long after expected1-3
The trials report a total of 383 patients, with 2 trials having actual enrollment of 293, and the other estimated.
Important missing comments or errors? Let us know.
Study covers chlorhexidine and povidone-iodine.
Keating et al., 30 Jun 2022, Randomized Controlled Trial, USA, this trial uses multiple treatments in the treatment arm (combined with PVP-I) - results of individual treatments may vary, trial NCT04478019 (history) (SHIELD). Contact: ns2@medicine.wisc.edu, dshirley@medicine.wisc.edu, jakeating@medicine.wisc.edu, SHIELD@medicine.wisc.edu, klhaight@medicine.wisc.edu, jperzynski@medicine.wisc.edu, mzimbric@medicine.wisc.edu.